Market chatter on GALT stock forecast focuses on trial enrollment pace, a leading indicator for regulatory timelines. Faster enrollment could accelerate value realization. Every investor in Galectin Therapeutics Inc. ( NASDAQ:GALT ) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are retail investors with 55% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. To track analyst ratings and price targets for $GALT, check out Quiver Quantitative's $GALT forecast page. Technical analysts reviewing GALT stock forecast identify a symmetrical triangle forming on the daily chart, indicative of an impending volatility breakout.